Vol 27, No 1 (2022)
Letter to the Editor
Published online: 2021-11-17

open access

Page views 4820
Article views/downloads 240
Get Citation

Connect on Social Media

Connect on Social Media

Neoadjuvant radiotherapy in triple-negative breast cancer: “the past should not steal the present or hide the future”

Nhu Hanh To12, Nina Radosevic-Robin3, Yazid Belkacemi124
Rep Pract Oncol Radiother 2022;27(1):180-181.

Abstract

NA

Article available in PDF format

View PDF Download PDF file

References

  1. Ho AY, Wright JL, Blitzblau RC, et al. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020; 108(1): 227–241.
  2. Soares RF, Garcia AR, Monteiro AR, et al. Prognostic factors for early relapse in non-metastatic triple negative breast cancer — real world data. Rep Pract Oncol Radiother. 2021; 26(4): 563–572.
  3. Roth SL, Audretsch W, Bojar H, et al. Retrospective study of neoadjuvant versus adjuvant radiochemotherapy in locally advanced noninflammatory breast cancer: survival advantage in cT2 category by neoadjuvant radiochemotherapy. Strahlenther Onkol. 2010; 186(6): 299–306.
  4. Bondiau PY, Courdi A, Bahadoran P, et al. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2013; 85(5): 1193–1199.



Reports of Practical Oncology and Radiotherapy